SCHEMBL6136707

SCHEMBL6136707

CCC(C)OP(=O)(O)O[Si](C)(C)C

nearest known ligand 0.31

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LAP3 P28838 1/20 0.31
METAP1 P53582 1/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL497286 0.83 LAP3 (0.39) LAP3METAP1MMP1MMP2MMP3
SCHEMBL2185946 0.81 LAP3 (0.37) LAP3METAP1MMP1MMP2MMP3
SCHEMBL27714875 0.79 CTSA (0.39)
SCHEMBL11410937 0.77 CTSA (0.37) LAP3METAP1MMP1MMP2MMP3
SCHEMBL13557334 0.77 MMP1 (0.38) LAP3METAP1MMP1MMP2MMP3
SCHEMBL2863833 0.75 BTN3A1 (0.38) LAP3METAP1
SCHEMBL11409309 0.75 PPARD (0.39) LAP3METAP1MMP1MMP2MMP3
SCHEMBL6014564 0.73 LAP3 (0.41) LAP3METAP1
SCHEMBL485995 0.73
SCHEMBL14777095 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353949-A1 ONE-COMPONENT BURN-IN SYSTEM COVESTRO DEUTSCHLAND AG (DE) 2025-11-20 US disclosed
US-20250297054-A1 BLOCKED POLYISOCYANATES COVESTRO DEUTSCHLAND AG (DE) 2025-09-25 US disclosed
US-20250163207-A1 BLOCKED POLYISOCYANATES COVESTRO DEUTSCHLAND AG (DE) 2025-05-22 US disclosed
WO-2025087730-A1 METHOD FOR PREPARING A POLYISOCYANATE BASED ON 1,5-PENTAMETHYLENE DIISOCYANATE COVESTRO DEUTSCHLAND AG (DE) 2025-05-01 WO disclosed
EP-4545579-A1 PROCESS FOR THE PREPARATION OF A POLYISOCYANATE BASED ON 1,5-PENTAMETHYLENE DIISOCYANATE Covestro Deutschland AG (DE) 2025-04-30 EP disclosed
EP-1054029-B1 Method of improving stability of aromatic polycarbodiimides ROHM & HAAS (US) 2005-12-28 EP disclosed
US-6797800-B2 VIA CATALYST SUCH AS TETRABUTYLPHOSPHONIUM-BENZOTRIAZOLEATE IN METHANOL; FOR PRODUCING POLYURETHANE PLASTICS AND COATING POWDERS BAYER AKTIENGESELLSCHAFT (DE) 2004-09-28 US disclosed
US-20030013872-A1 Method of dimerizing isophorone diisocyanate BAYER AKTIENGESELLSCHAFT (DE) 2003-01-16 US disclosed
US-6362247-B1 DEACTIVATION PHOSPHOLENE CATALYSTS ROHM AND HAAS COMPANY 2002-03-26 US disclosed
EP-1054029-A1 Method of improving stability of aromatic polycarbodimides ROHM AND HAAS COMPANY (US) 2000-11-22 EP disclosed
US-5476892-A Mixing with a silylated acid; good color and activity properties; producing polyurethane foams BAYER AKTIENGESELLSCHAFT (DE) 1995-12-19 US disclosed
US-5342881-A Process for the standardization and stabilization of organic polyisocyanates and the stable products of this process BAYER AKTIENGESELLSCHAFT (DE) 1994-08-30 US disclosed
US-5260481-A With silylated acid BAYER AKTIENGESELLSCHAFT (DE) 1993-11-09 US disclosed
US-5258508-A Process for the preparation of oligomeric polyisocyanates and their use BAYER AKTIENGESELLSCHAFT (DE) 1993-11-02 US disclosed
US-5202358-A Catalytic carbodiimidizing isocyanater groups BAYER AKTIENGESELLSCHAFT (DE) 1993-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013872-A1 Method of dimerizing isophorone diisocyanate PUF60, TST, UROD LAP3 792/4885METAP1 2369/4885MMP1 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.